Presently, targeted therapies for the treatment of metastatic melanoma are stratified based on tumor stage (e.g., stage IV), mutant genotype (e.g., MEK/BRAF inhibitors), or the expression levels of key biomarkers such as PD-L1 [45,46]. The gene discussed is BRAF; the disease is metastatic melanoma.